First‐line Bismuth‐containing Five‐day Concomitant Quintuple Therapy for Helicobacter Pylori Eradication
- 23 June 2015
- journal article
- research article
- Published by Wiley in Helicobacter
- Vol. 21 (2), 100-105
- https://doi.org/10.1111/hel.12241
Abstract
Bismuth-containing, short course, quintuple concomitant therapy appears to be an effective and safe therapeutic option for the first-line H. pylori eradication, particularly in populations with high resistance.Keywords
This publication has 30 references indexed in Scilit:
- Efficacy of 5-Day Levofloxacin-Containing Concomitant Therapy in Eradication of Helicobacter pylori InfectionGastroenterology, 2012
- Management ofHelicobacter pyloriinfection—the Maastricht IV/ Florence Consensus ReportGut, 2012
- 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trialThe Lancet, 2011
- Helicobacter pylori treatment in the era of increasing antibiotic resistanceGut, 2010
- Meta-analysis: Four-Drug, Three-Antibiotic, Non-bismuth-Containing "Concomitant Therapy" Versus Triple Therapy for Helicobacter pylori EradicationHelicobacter, 2009
- A Report Card to Grade Helicobacter pylori TherapyHelicobacter, 2007
- The global health burden of infection‐associated cancers in the year 2002International Journal of Cancer, 2006
- H pylori antibiotic resistance: prevalence, importance, and advances in testingGut, 2004
- The optimal antibiotic combination in a 5‐day Helicobacter pylori eradication regimenAlimentary Pharmacology & Therapeutics, 1999